Navigation Links
Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results
Date:6/2/2010

ps, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.


'/>"/>
SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... -- Quest Diagnostics Incorporated (NYSE: DGX ), the world,s ... is scheduled to speak at the Jefferies 2015 Global ... the company,s President and CEO, will discuss the company,s ... scheduled for Tuesday, June 2, 2015 at 8:00 a.m. ... live during the conference and will be available to ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ) has ... "Cell Therapy - Technologies, Markets and Companies" ... describes and evaluates cell therapy technologies and methods, ... role in the practice of medicine. Hematopoietic stem ... marrow transplants. Role of cells in drug discovery ...
(Date:5/28/2015)... CARLOS, Calif. , May 28, 2015 /PRNewswire/ ... testing, today announced a study published in ... the Panorama single-nucleotide polymorphism (SNP)-based non-invasive prenatal test ... the first trimester. A study ... that complete molar pregnancies occur in about 1 ...
(Date:5/28/2015)... Mass. , May 28, 2015 RXi ... focused on discovering and developing innovative therapeutics, primarily in ... pricing of a public offering of 26 million units ... share for gross proceeds of approximately $10.4 million. Each ... (ii) a 13-month overallotment purchase right to purchase 0.50 ...
Breaking Biology Technology:Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3
... HUBBARD, Ohio, Jan. 12 NanoLogix, Inc. (OTC: NNLX) ... update. NanoLogix welcomes Daniel Barnhizer and Jeff Long to ... professor of law at Michigan State University ... the areas of business, contract, securities, and commercial law. ...
... PARIS, January 12 The French agency Agence ... Dr. Kamel Senouci as,Program Director for the SIVAC ... program aims at contributing to,the development of national ... in Africa and six in Asia. These committees ...
... PARK, Ill. and SANTA ANA, Calif., Jan. 12 ,Abbott ... EYE ) announced,today a definitive agreement for Abbott ... total transaction value of approximately $2.8 billion, inclusive,of estimated net ... Ana, Calif., AMO,is a global leader in ophthalmic care, comprised ...
Cached Biology Technology:NanoLogix Inc. Appoints Two New Directors and Provides Operations Update 2NanoLogix Inc. Appoints Two New Directors and Provides Operations Update 3French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees) 2French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees) 3Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 2Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 3Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 5Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 6Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 7
(Date:4/27/2015)... FORT LAUDERDALE, Fla. , Apr. 27, 2015 /PRNewswire/ ... provider of access control and security systems is pleased ... joined the company as a consultant and member of ... Bedore is widely known as a thought leader ... Socrates Distance Learning Technology Group, and has published studies ...
(Date:4/20/2015)... The announcement comes as demand for fire ... Ireland,s foremost records management company, has ... an impressive track record of clients within the first 12 ... management sector in Dubai . As a ... employ a further eight staff members at its Irish headquarters. ...
(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... the First World War, a lethal virus known as ... United States, Europe and Asia in three convulsive waves. ... to 100 million victims, most of whom succumbed to ... died within days of the first symptoms. ...
... ANDS ) announced today that it will present ... Monday, February 16, 2009 at 1:00 p.m. PST (4:00 p.m. ... Laguna Niguel. Steve Worland, Ph.D., President and Chief Executive Officer ... clinical programs: ANA598 and ANA773 in hepatitis C and ANA773 ...
... in eight women in the United States will receive a ... the second leading cause of cancer-related death in women. Now ... treatment for each patient. "Our research shows that there ... getting any treatment at all, other than a lumpectomy," explains ...
Cached Biology News:Shades of 1918? New study compares avian flu with a notorious killer from the past 2Shades of 1918? New study compares avian flu with a notorious killer from the past 3Shades of 1918? New study compares avian flu with a notorious killer from the past 4Shades of 1918? New study compares avian flu with a notorious killer from the past 5Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference 2New test for breast cancer will help guide treatment choices 2
... Detection System is intended for use in ... by an in-house validated method for in ... target of interest. • ... a hybridization capture assay designed to detect ...
... maximum packaging efficiencies of cDNA and genomic DNA ... a test insert with Novagen's l vector arms, ... 10^8 pfu/g ligated l control DNA) are typically ... use; simply add up to 5 g of ...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Biology Products: